Brief: Inhibikase Therapeutics Reports First Quarter Financial Results And Highlights Recent Period Activity
15/05/2023 13:34
Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT PERIOD ACTIVITY
* INHIBIKASE THERAPEUTICS INC - NET LOSS FOR QUARTER WAS
$0.16 PER
SHARE
* INHIBIKASE THERAPEUTICS INC - CASH AND CASH EQUIVALENTS
AND
MARKETABLE SECURITIES WERE $25.7 MILLION AS OF MARCH 31, 2023
* INHIBIKASE THERAPEUTICS INC - EXPECTS EXISTING CASH AND
CASH
EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO Q4 OF
2024
Source text for Eikon: ID:nPn9fCRSqa
Further company coverage: IKT.O
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share